Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

How Donor Natural Killer (NK) Cells Are Prepared for Cancer Therapy: A Patient’s Guide

Written by Dr. David Greene, MD, PhD, MBA on July 14, 2026

Table of Contents

If you or a loved one is researching cellular immunotherapy options for cancer, you may have come across the term NK cell therapy — a treatment approach that uses natural killer cells, either from the patient or from a healthy donor, to help the immune system target abnormal cells. Because this field moves quickly and involves specialized lab science, it’s easy to find information online that is outdated, oversimplified, or overstated.

This article breaks down, in plain language, how donor-derived NK cells are actually screened, separated, and grown in a laboratory before being used therapeutically — and what the current scientific evidence does and does not support. It draws on an interview with clinicians at an R3 Stem Cell partner clinic in Tijuana, Mexico, cross-checked against peer-reviewed research and clinical trial data.

What Are Natural Killer (NK) Cells?

Natural killer cells are a subset of lymphocytes — the same broad category of white blood cells that includes T cells and B cells. Unlike T cells, which need to be “trained” to recognize a specific target, NK cells are part of the innate immune system and can identify stressed or cancerous cells on contact.

This quality makes NK cells attractive for cancer research: in theory, they can respond to tumor cells that have learned to hide from other parts of the immune system.

Autologous vs. Allogeneic NK Cells

There are two general ways to source NK cells for therapy:

Approach

Source

Key Consideration

Autologous

The patient’s own blood

Avoids donor-matching issues, but a cancer patient’s own NK cells may already be reduced in number or function

Allogeneic

A healthy, screened donor

Provides robust, fully functional cells, but requires rigorous donor screening and compatibility testing

Choosing between these two paths involves real trade-offs, and patients researching options may find it helpful to review a broader breakdown of the pros and cons of autologous and allogeneic stem cell sourcing before deciding which model fits their situation. The process described by R3 Stem Cell’s clinical team uses the allogeneic (donor-derived) model, collecting NK cells from healthy donors rather than from the patient.

Step 1: Donor Screening

Before any donor blood is used, it must pass safety testing. This typically includes screening for transmissible infectious diseases and evaluating the blood for any factors that could trigger an adverse immune reaction in the recipient. This mirrors standard practice across blood and cell-donation programs worldwide, where donor eligibility criteria and infectious disease testing are foundational safety requirements.

Step 2: Separating White Blood Cells from Red Blood Cells

Once donor blood is confirmed safe for use, the first separation step divides red blood cells from white blood cells, since NK cells — like T cells and B cells — belong to the white blood cell population. This is typically done using centrifugation, a process that spins the blood sample at high speed so components separate by density and molecular weight.

Step 3: Isolating NK Cells from Other Lymphocytes

White blood cells include several different lymphocyte types, and only the NK cell fraction is used for this therapy. Laboratories distinguish NK cells from other lymphocytes using surface marker (antigen) identification.

The clinicians interviewed identified CD16 as a key marker used in this process. This is accurate, but it’s worth adding some clinical context for patients: CD16 is one of two markers most commonly used together to define NK cells in research and clinical laboratories. The combination of CD56-positive, CD3-negative status is generally considered the primary way to identify an NK cell, while CD16 identifies the specific NK cell subset capable of a targeting function called antibody-dependent cellular cytotoxicity (ADCC). This marker-based sorting sits at the center of how stem cells affect the immune system more broadly, since precise cell identification is what allows a lab to isolate a functionally active population rather than a mixed lymphocyte sample.

Step 4: Laboratory Expansion of NK Cells

A donor blood draw does not naturally contain enough NK cells to produce a meaningful clinical dose. After isolation, the NK cell fraction — which may start in the range of low millions of cells — is cultured under controlled laboratory conditions designed to stimulate proliferation, with the goal of reaching a therapeutic cell count.

This expansion step relies heavily on signaling proteins called cytokines. Multiple academic centers and biotechnology companies have published different expansion methods, including approaches using IL-2, IL-15, and IL-21, and engineered “feeder cell” systems, aimed at improving both the quantity and quality of expanded NK cells. Patients unfamiliar with this terminology may find it useful to review a plain-language explanation of what cytokines are and how they direct immune activity before evaluating a specific expansion protocol.

Step 5: Individualized Dosing

According to the clinical team, dosing is not one-size-fits-all. Several factors are weighed for each patient, including age, body weight, and cancer type. This individualized approach is consistent with how adoptive cell therapies are generally dosed in clinical research settings, where body weight-based or fixed-dose escalation schemes are common in early-phase trials.

Step 6: Administration

Once expanded and dosed, NK cells are administered in one of two ways, depending on the clinical scenario:

Intravenous (IV) infusion — cells circulate systemically, allowing them to reach tumor sites throughout the body

Intratumoral injection — cells are delivered directly into an accessible tumor mass

Both routes have precedent in published and ongoing clinical research, with the choice generally depending on tumor location, accessibility, and treatment goals.

What Does the Current Evidence Show?

This is the section where patients most need clear, unembellished information.

What’s well established: NK cells have a recognized, biologically plausible role in tumor surveillance, and their basic biology is well characterized in the scientific literature. Multiple early-phase clinical trials of donor-derived NK cell therapy — for conditions including relapsed/refractory lymphoma, leukemia, and multiple myeloma — have reported that infusions can be administered with a manageable safety profile, and some have shown meaningful response rates.

What remains investigational: as of 2026, no NK cell therapy has received full, standard FDA approval for routine treatment of cancer. Understanding why requires some familiarity with how the agency currently classifies cell-based products. Patients researching this space often benefit from reading about the relationship between stem cells, NK cell products, and current FDA oversight, as well as the more technical distinction covered in the 351 vs. 361 classification framework for human cell and tissue-based products, which determines how heavily a given cell product is regulated.

Practical implication for patients: if you’re evaluating a clinic offering NK cell therapy, it’s reasonable to ask what specific clinical data supports the protocol being offered, what regulatory framework governs the treatment where it’s administered, and how the cell product’s purity, potency, and dose are verified before infusion.

Why Manufacturing Quality Matters

The multi-step process described above — donor screening, cell separation, marker-based purification, and controlled expansion — exists because the quality of the final NK cell product directly affects both safety and potential efficacy. A poorly characterized or contaminated cell product carries real risks, including infection transmission or infusion of the wrong cell type.

This is one of several reasons why choosing the right regenerative medicine clinic matters as much as choosing the therapy itself. Reputable programs also build in a structured evaluation process before treatment begins, which is why many clinicians emphasize the role of a thorough consultation in regenerative medicine as a first step, not a formality.

R3 Stem Cell’s Tijuana-based clinical team described this layered process — donor screening, marker-based isolation, laboratory expansion, and individualized dosing — as core to how they prepare donor NK cell products for patients. Patients weighing this option sometimes also compare it against domestic alternatives, and a side-by-side look at stem cell therapy in the U.S. versus Mexico can help frame that decision, along with a broader look at what it means to pursue stem cell treatment in Mexico specifically.

Frequently Asked Questions

Are donor NK cells safe for the recipient?

Donor blood is screened for infectious disease before use, which is a standard safety step across cell and blood therapy programs. As with any cellular therapy, patients should discuss specific risks, including possible immune reactions, with their treating physician.

How is an NK cell different from a T cell?

Both are lymphocytes, but T cells require antigen-specific priming to recognize a target, while NK cells can respond to abnormal cells without that priming step — a feature of the innate immune system.

Is NK cell therapy a cure for cancer?

No current NK cell therapy is established as a standalone cure. It is being studied, often alongside other treatments, as a way to help the immune system target cancer cells. Patients should treat it as part of an evolving, evidence-based treatment landscape rather than a guaranteed outcome.

How many NK cells are needed for a treatment?

This varies by protocol and patient factors, but published expansion approaches commonly aim for cell counts in the tens to hundreds of millions, with some specialized methods achieving higher yields.

Is traveling internationally for NK cell therapy worth considering?

It depends on the individual’s diagnosis, available domestic options, and the specific clinic’s protocols. Patients weighing this question often research it directly, including whether international stem cell therapy is a reasonable option given their diagnosis and circumstances.

Contact Us